e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Novel approaches and evidence for drug development in respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Differential effects of budesonide and fluticasone propionate on bronchial epithelial barrier function
I. Heijink, M. Jonker, N. Ten Hacken, E. Telenga, D. Postma, M. Van den Berge (Groningen, Netherlands)
Source:
International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Session:
Novel approaches and evidence for drug development in respiratory diseases
Session type:
Poster Discussion
Number:
3331
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Heijink, M. Jonker, N. Ten Hacken, E. Telenga, D. Postma, M. Van den Berge (Groningen, Netherlands). Differential effects of budesonide and fluticasone propionate on bronchial epithelial barrier function. Eur Respir J 2014; 44: Suppl. 58, 3331
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Differential effects of budesonide and fluticasone propionate on expression of lactotransferrin in airway epithelium
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Initial interaction of fluticasone propionate with ciliated respiratory epithelium
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Anti-inflammatory effects of formoterol and fluticasone propionate in bronchial epithelial cells
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Interaction between aclidinium bromide and formoterol fumarate in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Enhanced inflammatory gene expression in bronchial epithelial cells from asthmatic patients: Attenuation by a Brd4 mimic
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Budesonide and fluticasone propionate exertdifferential effects on human bronchial epithelial cells exposed to streptococcus pneumoniae and viral mimetic
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Fluticasone furoate maintains epithelial homeostasis via leptin/leptin receptor pathway in nasal cells
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Differential effect of fluticasone on Poly(I:C) induced TSLP secretion by bronchial epithelial cells from asthmatic children
Source: International Congress 2016 – Mechanisms of disease
Year: 2016
COPD airway epithelium secretion attracts and activates neutrophils
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Differential effects of budesonide and fluticasone propionate on bacterial recognition receptors in COPD macrophages
Source: International Congress 2016 – Airway response to infection
Year: 2016
B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
The role of the K
Ca
3.1 channel in the regulation of airway mucus hypersecretion in asthma
Source: International Congress 2014 – Mechanistic studies of the airway epithelium
Year: 2014
T regulatory cells: Immunomodulation by budesonide and formoterol on COPD patients
Source: International Congress 2015 – Mucosal immunology: what’s new in 2015
Year: 2015
Allergen exposed primary human bronchial epithelial cells have inhibited transport of salbutamol sulphate only when functional organic cation tranporters are present
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept